{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004115","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.527499+00:00","generated_at":"2026-06-20T17:48:37.448514+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nurix Therapeutics outlines 2023 clinical milestones for BTK degraders and CBL-B inhibitor at JPM Conference","bullets":["NX-2127 BTK degrader: clinical update and regulatory strategy in H2 2023.","NX-5948 BTK degrader: initial Phase 1a data and dose for expansion in H2 2023.","NX-1607 CBL-B inhibitor: Phase 1a data and dose for expansion in H2 2023.","Cash, equivalents and marketable securities of $413.6M as of Aug 2022; runway into Q4 2024.","Raised $115M in 2022; expects to select new development candidate in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004115","json":"https://secwatch.observer/filing/0001193125-23-004115.json","markdown":"https://secwatch.observer/filing/0001193125-23-004115.md","text":"https://secwatch.observer/filing/0001193125-23-004115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000119312523004115/0001193125-23-004115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000119312523004115/d426013d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:48:37.448514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}